Search
Acetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawn[A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978. … [L1704] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[L1703]
Categories: Compounds used in a research, industrial, or household settingLutein
go.drugbank.com/drugs/DB00137ApprovedNutraceuticalLutein is an xanthophyll and one of 600 known naturally occurring carotenoids. … Lutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots.
Oteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalThe main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU.
Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20Human botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115Approved[L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism. … Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut.
Categories: Human Immunoglobulin GSarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 … Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because
Betibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigationaldonor due to the risks of graft rejection, graft-versus-host disease, and other treatment-related toxic effects. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia
Voclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigationalWithin 10 years of being diagnosed with SLE, 5-20% of those suffering from LN develop end-stage kidney disease, a fatal condition. … LN is a significant cause of renal failure, morbidity, and death in patients with SLE.
Amrubicin
go.drugbank.com/drugs/DB06263InvestigationalIn 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006.
Pegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.
Foscarbidopa
go.drugbank.com/drugs/DB16171ApprovedFoscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult
Mixtures: Produodopa 240 mg/ml + 12 mg/ml Infusionslösung